Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy…
Novartis announced that the U.S. Food and Drug Administration (FDA) granted iptacopan (LNP023) Breakthrough Therapy Designation (BTD) in paroxysmal nocturnal hemoglobinuria (PNH) and…
Read More...
Read More...
